Figure 2.

IC87114 attenuates airway inflammation in ovalbumin/lipopolysaccharide (OVA/LPS)-induced asthma. (a) Lung tissues and bronchoalveolar lavage fluid (BALF) cells obtained from OVA/LPS-treated mice, saline (SAL)-treated mice and OVA/LPS-treated mice administered 1 mg kg⁻¹ IC87114 were stained with hematoxylin and eosin (upper) and Diff-Quick solution (lower). Magnification × 100. (b) Phosphoinositol 3-kinase (PI3K) activity was measured as described in the Materials and methods (n=6 animals per experimental group). (c) Immunoblotting and densitometric analyses (lower) were performed with an anti-p-AKT or AKT antibody. (d) Immunoblotting was performed for nuclear factor-κB (NF-κB) or IκBα after isolating nuclear, cytosolic, and total fractions. (e) Densitometric analyses of nuclear NF-κB p65/nuclear histone, cytosolic p65/cytosolic tubulin and IκBα/β-actin were performed. (f) Immunoblotting was performed with an anti-Mucin5AC antibody in lung tissues (upper) and in BALF (CBB staining for loading control). The lines with SAL and OVA/LPS represent two samples from the same conditions. In (c) and (e), values are presented as the mean (±s.e.m.) fold change relative to the control (SAL) group (n=6 animals per experimental group). Mice challenged with saline (SAL) were used as the control group. ^#P<0.05 versus SAL; *P<0.05 versus OVA/LPS only.